GLP-1 receptor agonists like semaglutide and tirzepatide act on incretin pathways through GLP-1 and GIP receptors, with central appetite suppression and slowed gastric emptying as primary mechanisms
This observation is particularly important because it demonstrates that these drugs can remain effective even in the absence of the MC4R pathway, which is traditionally thought to play a key role in regulating energy balance and appetite
Everything happens through a secure app or portal, with medication shipped in discreet, temperature-controlled packaging
Once all the medicine is injected, quickly pull the needle out
However, the emergence of modern obesity management medicines (OMMs), especially GLP-1 receptor agonists and dual incretin therapies such as semaglutide and tirzepatide, has dramatically changed the obesity treatment landscape
Of course, we also offer our signature IV infusion therapy and vitamin booster shots